| Dr Bruce Johnson, MD | |
|
3099 River Rd S, Salem, OR 97302-9754 | |
| (503) 518-1567 | |
| (503) 399-1229 |
| Full Name | Dr Bruce Johnson |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 38 Years |
| Location | 3099 River Rd S, Salem, Oregon |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1750386579 | NPI | - | NPPES |
| 029772 | Medicaid | OR |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | 15194 (Oregon) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Salem Hospital | Salem, OR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Willamette Ear Nose And Throat Llp | 5597737643 | 13 |
News Archive
Statistics show that the total number of Tasmanian children in state care has risen by 60% in six years. This is the second highest number of children per 1,000 in child protection in the Australia. This means more children are being removed from their families for issues such as substance abuse, mental health and family violence.
Chemists at the University of California, San Diego, have identified how a protein that accumulates in the brains of people with Alzheimer's disease interferes with the ability of cells to get rid of debris. They also found a natural mechanism by which this protein, amyloid beta, itself may be discarded.
VIVUS, Inc. today announced positive results from a phase 2 study evaluating the safety and efficacy of Qnexa®, an investigational drug, for the treatment of obstructive sleep apnea (OSA). VIVUS recently completed phase 3 development of Qnexa for the treatment of obesity and submitted a New Drug Application (NDA) to the FDA for that indication.
Drinking alcohol during pregnancy can lead to teratogenesis, the development of embryonic defects.
› Verified 6 days ago
| Entity Name | Willamette Ear Nose & Throat Llp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184821043 PECOS PAC ID: 5597737643 Enrollment ID: O20040809001365 |
News Archive
Statistics show that the total number of Tasmanian children in state care has risen by 60% in six years. This is the second highest number of children per 1,000 in child protection in the Australia. This means more children are being removed from their families for issues such as substance abuse, mental health and family violence.
Chemists at the University of California, San Diego, have identified how a protein that accumulates in the brains of people with Alzheimer's disease interferes with the ability of cells to get rid of debris. They also found a natural mechanism by which this protein, amyloid beta, itself may be discarded.
VIVUS, Inc. today announced positive results from a phase 2 study evaluating the safety and efficacy of Qnexa®, an investigational drug, for the treatment of obstructive sleep apnea (OSA). VIVUS recently completed phase 3 development of Qnexa for the treatment of obesity and submitted a New Drug Application (NDA) to the FDA for that indication.
Drinking alcohol during pregnancy can lead to teratogenesis, the development of embryonic defects.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Bruce Johnson, MD 3099 River Rd S, Salem, OR 97302-9754 Ph: (503) 518-1567 | Dr Bruce Johnson, MD 3099 River Rd S, Salem, OR 97302-9754 Ph: (503) 518-1567 |
News Archive
Statistics show that the total number of Tasmanian children in state care has risen by 60% in six years. This is the second highest number of children per 1,000 in child protection in the Australia. This means more children are being removed from their families for issues such as substance abuse, mental health and family violence.
Chemists at the University of California, San Diego, have identified how a protein that accumulates in the brains of people with Alzheimer's disease interferes with the ability of cells to get rid of debris. They also found a natural mechanism by which this protein, amyloid beta, itself may be discarded.
VIVUS, Inc. today announced positive results from a phase 2 study evaluating the safety and efficacy of Qnexa®, an investigational drug, for the treatment of obstructive sleep apnea (OSA). VIVUS recently completed phase 3 development of Qnexa for the treatment of obesity and submitted a New Drug Application (NDA) to the FDA for that indication.
Drinking alcohol during pregnancy can lead to teratogenesis, the development of embryonic defects.
› Verified 6 days ago
Jared Hiebert, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 3099 River Rd S Ste 150, Salem, OR 97302 Phone: 503-581-1567 Fax: 503-399-1229 | |
Dr. Lawrence Thomas Eschelman, M.D. Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 3585 Cherokee Dr S, Salem, OR 97302 Phone: 503-399-0710 Fax: 503-763-1591 | |
Dr. Christopher Thomas Prze, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 3099 River Rd S, Salem, OR 97302 Phone: 503-581-1567 Fax: 503-399-1229 | |
Dr. John Donovan, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 3099 River Rd S, Salem, OR 97302 Phone: 503-581-1567 Fax: 503-399-1229 | |
Dr. Suzanne Forman Strand, DO Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 3099 River Rd S Ste 150, Salem, OR 97302 Phone: 503-581-1567 | |
Dr. Clark Thompson, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 3099 River Rd S, Salem, OR 97302 Phone: 503-581-1567 Fax: 503-399-1229 |